The independent medical news service

Results of the PRINCE trial point to the potential of LuPSMA plus pembrolizumab for the treatment of metastatic castration-resistant prostate cancer with high expression of PSMA.

Supplementing androgen deprivation therapy with 2 years of an abiraterone acetate-based regimen significantly boosts the survival of men with high-risk nonmetastatic prostate cancer, show STAMPEDE results.

The addition of abiraterone acetate to standard therapy with docetaxel plus androgen deprivation therapy significantly improves the overall survival of patients with de novo metastatic castration-sensitive prostate cancer, report the PEACE-1 investigators.

The final analysis of the ARCHES trial has demonstrated a significant overall survival boost with the addition of enzalutamide instead of placebo to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting.

Slow recruitment and low event rates have led to early termination of the PRONOUNCE trial, which hoped to determine the relative cardiovascular safety of gonadotropin-releasing hormone antagonists and agonists in men with prostate cancer.

The number of new cancer diagnoses during the first year of the COVID-19 pandemic was lower than in the prepandemic period, report US researchers.

Phase 2 study data show that the PARP inhibitor talazoparib has antitumor activity in men with heavily pretreated metastatic castration-resistant prostate cancer bearing DNA damage response alterations in genes associated with homologous recombination repair.

Men with localized prostate cancer undergoing active surveillance who follow a high-intensity interval training regimen can expect improvements in cardiorespiratory fitness and indicators of biochemical progression, early findings indicate.

The Stockholm3 risk prediction tool performs at least as well as prostate-specific antigen screening for the detection of clinically significant prostate cancer, research suggests.

A US study has found no significant difference in outcomes between African–American and White men undergoing active surveillance for intermediate-risk prostate cancer.

The addition of bone resorption inhibitors to abiraterone acetate plus prednisone is associated with improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases, especially if they have high-volume disease, researchers report.

Nonmetastatic castration-resistant prostate cancer patients aged 80 years and older benefit from treatment with second-generation androgen receptor inhibitors, suggests a pooled analysis of three trials.

Black men with nonmetastatic prostate cancer were significantly less likely than their White counterparts to undergo prostatectomy during the initial wave of the COVID-19 pandemic, reports a US research team.

A population-based, screening-by-invitation trial has demonstrated that a combined MRI-guided plus standard biopsy approach is noninferior to standard biopsy with regard to the detection of clinically significant prostate cancer in men with increased prostate-specific antigen levels.

Common treatments for metastatic castration-resistant prostate cancer are not associated with significant cognitive decline in older men, research suggests.

Updated safety data from the EORTC 1333/PEACE-3 trial show a marked reduction in the risk for fractures with the use of bone protecting agents in men with metastatic castration-resistant prostate cancer and bone metastases.

Regular prostate cancer screening in young African–American men significantly reduces the likelihood of metastatic disease at the time of diagnosis, show study findings reported at the 2021 ASCO Annual Meeting.

The combination of bipolar androgen therapy and nivolumab elicits responses and is well tolerated by men with metastatic castration-resistant prostate cancer, indicate phase 2 findings.

Supplementing standard of care treatment with lutetium-177-prostate-specific membrane antigen-617 significantly boosts the outcomes of heavily pretreated men with PSMA-positive metastatic castration-resistant prostate cancer, say the VISION investigators.

The benefit offered by olaparib in metastatic castration-resistant prostate cancer is attenuated when a more active standard of care is used as the comparator, suggests a network analysis of the PROfound and CARD trials.